Novonesis to build next generation enzyme production facility in India. Novonesis will invest €600 million to expand its site in Patalganga and build a state-of-the-art facility. This marks another step in the company's long-term growth strategy and continued investment in its global production footprint to meet increasing demand. COPENHAGEN, Denmark - September 2, 2026. Novonesis will expand its facility in Patalganga and build one of the world's most advanced enzyme production facilities. The €600 million investment will increase Novonesis' production capacity to meet rising worldwide demand for the company's biosolutions and strengthen the flexibility and resilience of its global supply network. The Patalganga expansion is a milestone in Novonesis' strategy and is key to achieving the company's growth ambitions. The facility, which is expected to be fully operational in 2030, will produce enzymes for a broad range of industries, including biofuels, household care, and food and beverages. Ester Baiget, President & CEO: "This is an important step in executing our strategy and reflects our continued commitment to investing for sustainable growth. The expansion strengthens our ability to support customers around the world and enables us to continue creating long-term value for our shareholders." This state-of-the-art facility will be integrated into the company's global production footprint and bring Novonesis closer to customers across the Middle East, India, and Africa. These markets represent an important and growing part of the company's business and are expected to grow faster than developed markets in the coming years. Anders Lund, Chief Operating Officer: "As demand for biosolutions continues to grow across industries and regions, expanding our global production capacity is a priority. The Patalganga expansion will strengthen our scale, operational resilience, efficiency, and supply flexibility. Just as importantly, it brings us closer to customers in key growth markets, enabling us to meet their expectations and deliver on our long-term growth targets." Strengthening global production capabilities Patalganga is part of a series of investments Novonesis has made to strengthen its global production setup and serve customers more effectively. Facilities in Rayong, Thailand; Franklinton, North Carolina; Taicang, China; Araucaria, Brazil; and West Allis, Wisconsin, have also been expanded as part of this effort. The investments align with the company's strategy and previously communicated capital expenditure plans. Setting a new standard for sustainable biosolutions production The Patalganga facility will be built to use less water and energy. Freshwater recycling will reduce the amount of water the site draws, while integrated heat pumps will lower the energy required to operate it. Together, these measures will put the facility on a path toward lower Scope 1 and 2 emissions. "Every facility we build should produce more with less. Patalganga brings together what we have learned across our production footprint and takes us another step toward zero-emission production," says Anders Lund. | Media Relations | / | | Jens Gamborg Head of External Communication Phone: + 45 30 77 71 82 [email protected] | / | About Novonesis Novonesis is leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries around the world, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 11,000 people worldwide work closely with our partners and customers to transform business with biology.

Novonesis expands U.S. Workforce development efforts to build the next generation of biomanufacturing talent. New Nebraska biotechnology program and scholarship build on education and workforce partnerships across Novonesis' U.S. communities. Blair, Nebraska, Aug. 26, 2026 (GLOBE NEWSWIRE) - As the U.S. biotechnology sector grows, developing the skilled workforce needed to turn scientific innovation into products at commercial scale is becoming increasingly important. Novonesis, a global leader in biosolutions, is expanding its U.S. workforce development efforts through partnerships that connect students with biotechnology education, hands-on learning and pathways to careers in biomanufacturing. The latest example is in Nebraska, where Novonesis is partnering with Metropolitan Community College (MCC) in Omaha to help shape the college's new biotechnology technician training program and is announcing the Novonesis Biomanufacturing Pathways Scholarship to help remove financial barriers for students pursuing careers in the industry. The partnership comes as Nebraska bioscience employment grew 6.3% from 2019 to 2023, compared with 2.9% growth across the state's overall private sector. "Building the future of biotechnology requires investing in people as well as science and technology," said Tue Micheelsen, President of Novonesis North America. "Across the country, we're working with educators and communities to help more people see what modern biomanufacturing looks like, develop the skills our industry needs and discover meaningful careers they may never have considered. These partnerships strengthen our workforce while helping the U.S. continue to lead in biotechnology." Connecting education with real-world careers Biomanufacturing uses biological processes to make products at commercial scale, requiring skilled employees to operate equipment, monitor production processes and help ensure products are made safely and consistently. Production roles are critical to Novonesis' ability to manufacture biosolutions used across industries ranging from agriculture and renewable energy to food, health and household care. Novonesis has a significant manufacturing footprint across the U.S., including North America's largest multipurpose enzyme manufacturing site in Franklinton, North Carolina; the nation's largest enzyme production site dedicated to biofuels in Blair, Nebraska; North America's largest liquid inoculants manufacturing site in Milwaukee; and its largest food cultures manufacturing site in West Allis, Wisconsin. Recruiting skilled people for production roles across this network is critical to supporting Novonesis' continued growth. Recognizing that workforce challenges can't be solved through hiring alone, Novonesis partners with educational institutions, workforce development organizations and community groups to build long-term talent pipelines in the regions where it operates. In Nebraska, that approach is taking shape through Novonesis' partnership with MCC. Company employees joined MCC's Business & Industry Leadership Team (BILT) to help shape a biotechnology program that reflects the skills employers need. The program includes a 15-week Biotechnology Fundamentals Microcredential providing a rapid-entry workforce option and a Biotechnology Career Certificate creating a pathway to continued education and careers in the field. Beginning this fall, students will complement classroom learning with production job shadowing and facility tours at Novonesis' Blair manufacturing site and Employer Spotlight sessions on campus. Students completing the micro credential will also have an opportunity to be screened by a Novonesis recruiter. The new Novonesis Biomanufacturing Pathways Scholarship adds another piece to that pathway, with an endowed fund to provide ongoing support for future students. The scholarship will help make biotechnology education more accessible while connecting financial support with industry-informed curriculum and real-world learning experiences. "The strongest workforce programs are built with employers at the table from the beginning," said Neil Riley, Associate Dean of Math and Natural Sciences at MCC. "Novonesis has been an invaluable partner, helping shape this program based on the skills biotechnology companies need today and tomorrow. Students graduate with technical knowledge, real-world experience, professional connections, and opportunities for financial assistance that can help them launch successful careers." Building the talent pipeline across the U.S. The Nebraska partnership is part of a broader Novonesis approach to building biotechnology talent by engaging students at multiple points in their education and career journeys. Engagement with K-12 students through field trips and in-class visits helps introduce younger generations to STEM and modern manufacturing before they begin making decisions about college, training and careers. Each October, Novonesis participates in Manufacturing Day, an initiative of The Manufacturing Institute, welcoming high school students to tour research laboratories and production facilities, interact with engineers and operators, and explore how biology is helping solve challenges related to food, fuel, health, and sustainability. Following Novonesis' 2025 Manufacturing Day flagship event in Franklinton, 93% of participating students said the experience introduced them to career pathways they had not previously considered. Community college partnerships are also a vital component of the company's talent acquisition approach. In North Carolina, Novonesis helped establish the BioWork program more than two decades ago alongside the North Carolina Biotechnology Center and community colleges, creating a certificate pathway into process technician careers. At the university and research level, Novonesis also collaborates with academic institutions to advance biotechnology innovation and capabilities. The company works with North Carolina State University and engages students through classroom outreach, site visits, scholarships, internships and other initiatives. In Davis, California, a U.S. National Science Foundation-funded collaboration brings together experts from Novonesis, Stanford University and the University of California, Davis to advance AI-enabled protein design and cell-free biomanufacturing. The collaboration demonstrates another role industry-academic partnerships can play in developing scientific capabilities and advancing U.S. biotechnology leadership. Together, these efforts, combined with internships and other programs across the company's 14 North American sites, reflect a workforce strategy that begins well before a job application with a goal of building awareness among younger students, creating accessible pathways into technical careers and connecting higher education and research with real-world biotechnology challenges. As Novonesis continues to grow its U.S. operations and capabilities, developing a skilled biotechnology workforce will be critical not only to the company's growth, but to the country's ability to scale biomanufacturing and maintain its leadership in biotechnology. About Novonesis Novonesis is a global biosolutions company leading the era of biosolutions. By leveraging the power of microbiology with science, Novonesis transforms the way the world produces, consumes, and lives. Across more than 30 industries, Novonesis biosolutions are already creating value for thousands of customers while benefiting the planet. With more than 11,000 employees worldwide, Novonesis partners with businesses and communities to better its world with biology. Attachments Kathy Humphrey Novonesis +19193397110 [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Novonesis reported 8% organic sales growth for the first half of 2026 and raised its full-year outlook. The Danish biosolutions company now expects organic sales growth of 7-8%, up from its previous 5-7% guidance, with adjusted EBITDA margin anticipated at the higher end of the 37-38% range. Food & Health Biosolutions grew 9% organically, whilst Planetary Health Biosolutions increased 7%. Both developed and emerging markets posted 8% growth. The adjusted EBITDA margin reached 37.7%, up 30 basis points year-on-year despite currency headwinds. The board approved an interim dividend of DKK 2.35 per share and announced an inaugural share buyback programme totalling €1 billion, to run from late 2026 through 2029.